// App-Quantinova.ai

: Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo).

Researchers

Presenter

  • Laeth George

Principal Investigators

  • Wei Wei

  • C. Marcela Diaz-Montero

  • Allison Martin

  • Neil Vyas

  • Arnab Basu

  • Katy Beckermann

  • Amanda Nizam

  • Christopher Eing Wee

  • Timothy D. Gilligan

  • Shilpa Gupta

  • Brian I. Rini

  • Moshe Chaim Ornstein

Medical Centers

  • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN

  • Taussig Cancer Institute, Cleveland, OH

  • Cleveland Clinic, Cleveland, OH

  • Cleveland Clinic Lerner Research Institute, Cleveland, OH

  • University of Alabama at Birmingham, Birmingham, AL

  • Vanderbilt, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03126331

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved